KNSA vs SIGA: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: SIGA is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. KNSA and SIGA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined KNSA and SIGA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Kiniksa Pharmaceuticals (Nasdaq: KNSA) is a commercial-stage biopharmaceutical company focused on immune-modulating and cardiovascular therapies. Its franchise is ARCALYST (rilonacept), an IL-1 blocker approved for recurrent pericarditis (a painful inflammatory condition of the heart lining) that it commercializes in the US under a collaboration with Regeneron. ARCALYST drove roughly $677.5 million of net product revenue in 2025, up about 62% from 2024, and the company reported roughly $214.3 million in Q1 2026 (up about 56% year over year), leading management to raise full-year 2026 ARCALYST guidance to roughly $930 to $945 million.

Full KNSA guide

SIGA Technologies is a commercial-stage pharmaceutical company built around one product, TPOXX (tecovirimat), an antiviral approved by the FDA to treat smallpox in both oral and intravenous forms. Because smallpox is eradicated in the wild, the real market is biodefense: governments stockpile TPOXX as a countermeasure against a deliberate or accidental release. SIGA's anchor customer is the US government through BARDA, which procures TPOXX for the Strategic National Stockpile under the 19C contract valued at up to roughly $629 million over a multi-year period. International governments in Europe, Asia-Pacific and elsewhere add incremental orders. In 2025 SIGA reported about $88 million in product revenue and roughly $24 million in pre-tax operating income, and it carries a strong balance sheet with well over $100 million in cash and no debt.

Full SIGA guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• KNSA drivers: ARCALYST adoption in recurrent pericarditis; Profitable growth profile.
• SIGA drivers: Long-dated US government stockpile demand; IV TPOXX and international expansion.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is single-product concentration: essentially all revenue depends on ARCALYST in one indication, so any competitive entry, reimbursement pressure, safety signal, or eventual loss of exclusivity would be material. For SIGA, sIGA carries unusually concentrated risk for its size.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick KNSA if you believe its drivers more; SIGA if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the KNSA and SIGA guides.

KNSA. As of July 2026, Kiniksa carried a market cap of roughly $5.2 billion against trailing revenue near $754 million and net income around $73 million, for a trailing P/E in the mid-70s. That multiple reflects both rare biotech profitability and expectations that ARCALYST keeps compounding toward the raised 2026 guidance of roughly $930 to $945 million.

SIGA. SIGA's earnings are lumpy and contract-driven, so a single quarter can look very different from the full year. Revenue depends on when a handful of large government orders ship, which means trailing multiples built on one quarter can badly mislead in either direction. A quarter with no international shipments can show a loss even when the annual picture is profitable. Any valuation view should weigh the durability and timing of stockpile procurement, the net cash position and discretionary special dividends rather than a simple price-to-earnings figure. These figures are drawn from company disclosures and should be checked against the latest filings before acting.

Headline figures (approximate, JULY 2026): KNSA shows revenue (ttm) ~$754M, net income (ttm) ~$73M, market cap ~$5.2B, p/e (trailing) ~74x; SIGA shows business model Single-product antiviral (TPOXX) sold mainly to governments, 2025 product revenue About $88 million (per company results), 2025 pre-tax operating income Roughly $24 million (company disclosed), q1 2026 revenue About $6.2 million with a small net loss; no international sales that quarter.

KNSA and SIGA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined KNSA and SIGA exposure against your real portfolio. It is not an investment adviser.